Project Grant R43TR004536
Award Date
1/15/24
Completion Date
1/14/25
Dollars Obligated
$331K
Federal Agency
National Center for Advancing Translational Sciences
Federal Grant Program
93.350
Assistance Type
Project Grant
Place of Performance
Wisconsin, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), provides $694,385 to fund research aimed at developing an ultrasound-based technique to enhance the delivery of adeno-associated virus (AAV) gene therapy to the heart. The primary awardee, the University of Virginia, will conduct studies to optimize the conditions for ultrasound cavitation to facilitate more efficient transduction of...
The National Center for Advancing Translational Sciences (NCATS), under the CFDA Program 93.350, awarded a $338,997 Project Grant to Mabswitch Inc. effective January 1, 2024 to December 31, 2024. The project aims to develop "LENTISAFE LIGANDS: MILD-ELUTION IMMUNOAFFINITY LIGANDS FOR ENRICHMENT AND PURIFICATION OF LENTIVIRAL VECTORS." The goal is to create switchable affinity ligands that can be used to selectively isolate and enrich functional lentiviral vectors from production...
The National Center for Advancing Translational Sciences (NCATS), through its CFDA 93.350 Federal Grant Program, awarded a $294,541 Project Grant to Cellular Vehicles Inc. on June 1, 2024. The purpose of this award is to develop an automated system for producing and delivering cell-laden hydrogel therapies. The project aims to create a novel, standardized process for formulating, encapsulating, and directly injecting cell-laden hydrogels into diseased tissues. This is intended to improve the...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) provides $1,095,274 to develop complementary biotherapeutic delivery platforms for enabling gene re-delivery. The award, effective August 1, 2024 through May 31, 2029, aims to pioneer innovative delivery strategies that overcome biological barriers and modulate immune responses to improve the effectiveness of adeno-associated virus...
This federal Project Grant award, valued at $540,524 and effective from March 1, 2025 to February 28, 2029, was provided by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" (CFDA 93.286) program. The primary objective of this award is to develop an enhanced RNA switch technology based on the T3H38 ribozyme, which can enable precise dose control and temporal regulation...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Program (CFDA 93.837), provides $317,285 to Rithim Biologics Inc. to develop a novel gene therapy approach to prevent ventricular tachycardia (VT) following myocardial infarction. The project aims to finalize the development of an epicardial gene painting catheter, verify ventricular-targeted transgene expression, and evaluate biodistribution and toxicity in an...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to demonstrate the efficacy of using hydrodynamic gene delivery for the treatment of hereditary tyrosinemia type 1 (HT1) and other rare genetic liver diseases. The $881,961 award to Hydrogene Therapeutics Inc. will fund the optimization of a vector system for safe genome integration and...
This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) provides $295,924 to Chesapeake Genomic Systems, LLC to develop an efficient, bacteria-independent workflow to produce completely vectorless supercoiled DNA (vlsDNA) molecules. The objectives are to optimize reaction conditions for a new DNA assembly technology called Cyclic Heteroduplex Thermostable Ligation Assembly (CHTLA) to maximize...
The National Center for Advancing Translational Sciences (NCATS), under CFDA 93.350, has awarded a $324,962 Project Grant to Tetmedical, Inc. to develop a technology for rapid, point-of-care and at-home testing of liver enzyme levels. The goal is to enable convenient and timely monitoring of drug-induced liver injury (DILI) and other sources of liver damage. The project aims to optimize tethered enzyme assays for detecting aspartate aminotransferase (AST) and alanine aminotransferase (ALT),...
This federal Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop a novel hydrogel-based system for delivering gene therapy to the heart. The primary awardee, Emory University, will engineer a hydrolysis-cleavable polyethylene glycol (PEG) hydrogel to target the epicardium and optimize cardiac transduction of gene therapy vectors. The total funding amount is $635,300.00, with a...